Venture capital can feel like a foreign language to scientists trained in the rigor of peer review and grant applications. This guide translates the essentials — from fund mechanics to term sheets — so you can evaluate whether VC is the right path for your science, and walk into your first meeting prepared.
At its core, venture capital is a financing model built for high-risk, high-reward companies. A venture capital firm raises a pool of money — called a fund — from institutional investors such as university endowments, pension funds, family offices, and high-net-worth individuals. These investors are known as Limited Partners, or LPs. The people who manage the fund, make investment decisions, and work directly with founders are called General Partners, or GPs. The GP's job is to deploy the fund's capital into early-stage companies, help those companies grow, and ultimately return a multiple of the original fund back to LPs.
A typical venture fund has a ten-year lifespan. During the first three to four years, the GP invests the capital. During the remaining years, the GP supports portfolio companies as they mature toward an exit — either an acquisition by a larger company or, less commonly, an initial public offering. When an exit occurs, the proceeds flow back to the fund, are distributed to LPs (after the GP takes a performance fee known as carried interest, typically 20%), and the cycle begins again. This structure means that VCs are not simply writing checks; they are making long-term bets on founders and technologies that they believe can generate outsized returns within a defined time horizon.
If your reference point for venture capital is Silicon Valley software startups, you need to recalibrate. Life sciences venture operates on a fundamentally different clock. A software company can ship a product in months and iterate based on user feedback. A therapeutics company may spend a decade and hundreds of millions of dollars navigating preclinical research, IND-enabling studies, and three phases of clinical trials before a single patient benefits. The regulatory environment — the FDA, EMA, and their global counterparts — imposes rigorous evidentiary standards that simply do not exist in consumer technology.
This has profound implications for how life sciences VCs think. They are accustomed to longer timelines, larger capital requirements, and binary risk events like clinical trial readouts that can make or break a company overnight. They also place enormous weight on intellectual property. In tech, speed and network effects create defensibility. In life sciences, patents, trade secrets, and data exclusivity are the moat. A VC evaluating your company will scrutinize your IP portfolio — what is patented, what is patentable, what is licensed from your university, and how broad the claims are — with the same rigor you apply to an experimental protocol.
The upside, however, is equally distinct. Life sciences companies that reach key milestones — proof of concept in animal models, an IND filing, positive Phase I data — experience dramatic step-ups in valuation. A pre-seed life sciences company might raise at a $5–10 million valuation; by the time it has Phase II data, that same company could be worth $500 million or more. VCs who invest early in the right science are rewarded handsomely, which is precisely why firms like Legacy focus on the earliest stages where the scientific signal is strongest and the market has not yet priced in the opportunity.
In tech, VCs bet on markets. In life sciences, VCs bet on mechanisms. The science is the product — and the scientist is the competitive advantage.
Here is the most important thing to understand: at the pre-seed and seed stage, a life sciences VC is not investing in a pitch deck. They are investing in you and your science. The polished narrative matters far less than the depth of your understanding, the rigor of your data, and your ability to articulate why your work matters for patients. VCs who specialize in early-stage life sciences — particularly those with scientific training themselves — can evaluate primary data, read your publications, and assess the mechanistic basis of your approach. What they are looking for is scientific conviction backed by reproducible evidence.
Beyond the science, VCs evaluate what is sometimes called founder-market fit. For scientist-founders, this means: Are you the person in the world best positioned to translate this research into a company? Do you understand not only the biology but the clinical unmet need it addresses? Can you attract collaborators, recruit a team, and make decisions under uncertainty? This does not mean you need an MBA or prior startup experience. It means you need intellectual honesty about what you know and what you will need to learn, and the willingness to build around your gaps.
Fundraising in life sciences typically follows a pattern, though the specifics vary by firm and stage. It begins with an introduction — often through a mutual contact, a technology transfer office, an accelerator, or increasingly through direct outreach by the founder or the VC. At Legacy, we also source founders through our research networks and AI-powered discovery tools, because we believe the best science often comes from scientists who are not yet plugged into the venture ecosystem.
After an initial conversation, if there is mutual interest, the VC will conduct diligence. In life sciences, this is substantive and scientific. Expect the GP or their advisors to review your publications, examine your data, speak with scientific references, evaluate your IP landscape, and assess the competitive environment. This process can take anywhere from a few weeks to several months. It is not unusual for a life sciences VC to consult with key opinion leaders in your therapeutic area or to engage patent counsel to evaluate freedom to operate.
If diligence goes well, the VC will present a term sheet — a non-binding document that outlines the key economic and governance terms of the proposed investment. This includes the amount of capital being invested, the valuation of your company (pre-money and post-money), the type of security being issued (equity, SAFE, or convertible note), and provisions around board seats, protective rights, and future financing. The term sheet is the starting point for negotiation, not the final word. You should always have legal counsel review it before you sign.
If you have reproducible results and a hypothesis for clinical application, it's worth a conversation. You don't need a finished business plan — you need a compelling scientific story and the willingness to explore what comes next.
Having worked with dozens of scientist-founders at the earliest stages, we see the same missteps repeatedly. Recognizing them in advance can save you months of frustration and help you enter the process with realistic expectations.
Intellectual property is the foundation of nearly every life sciences startup, and managing it correctly from the beginning is critical. If your research was conducted at a university, the institution almost certainly owns the IP under the Bayh-Dole Act. This means you will need to license it — typically through an exclusive license agreement negotiated with the university's technology transfer office (TTO). The terms of this license — including upfront fees, milestone payments, royalties, and the scope of exclusivity — will significantly affect your company's economics and attractiveness to investors.
Start the TTO conversation early, ideally before you begin fundraising. VCs will ask about your IP status in the first or second meeting, and uncertainty here is a red flag. Understand what has been filed (provisional patents, PCT applications, issued patents), what the claims cover, and what freedom-to-operate risks exist. If your work builds on foundational IP owned by others, identify those dependencies and have a strategy for addressing them — whether through licensing, designing around, or establishing that the prior art does not block your approach.
One crucial point: be careful about public disclosure. Under U.S. patent law, you have a one-year grace period after a public disclosure (such as a publication or conference presentation) to file a patent application. In most other jurisdictions, any public disclosure before filing destroys patentability entirely. If you are considering commercializing your research, discuss patent strategy with your TTO or a patent attorney before you publish or present.
There is no single right moment, but there are clear signals that it is time to explore the conversation. If you have generated reproducible data that supports a novel biological mechanism or therapeutic hypothesis, if you can articulate a clinical application for your work, and if you are genuinely considering whether a company is the right vehicle to advance your science — then it is worth reaching out. You do not need a business plan, a pitch deck, or a co-founder. You need curiosity about the process and openness to learning how venture capital might accelerate your research's impact.
The best early-stage VCs are not looking for polished entrepreneurs. They are looking for exceptional scientists with differentiated insights and the drive to see their work reach patients. A first conversation with a VC should feel more like a scientific discussion than a sales pitch. If it does not, you may be talking to the wrong firm.
The transition from scientist to founder is not a departure from your research. It is the most direct path to seeing your science change lives.
The venture world has its own vocabulary. Here are the terms you will encounter most frequently in early-stage fundraising.
The earliest institutional funding stage, typically $250K–$2M. At pre-seed, the company may not yet be formally incorporated. Investment is based primarily on the founder, the science, and a preliminary vision for clinical translation. This is where Legacy invests most frequently.
The next stage after pre-seed, typically $2M–$5M in life sciences. Seed capital is used to advance the science toward key milestones — such as proof of concept in relevant models, IND-enabling studies, or platform validation — that will support a larger Series A raise.
A non-binding document that outlines the proposed terms of an investment, including the amount of capital, valuation, type of security, governance provisions, and investor rights. Receiving a term sheet is a strong signal of intent, but it is not a binding commitment. Always review with legal counsel.
The reduction in a founder's ownership percentage that occurs when new shares are issued to investors. Dilution is a normal part of fundraising. What matters is not your percentage but the value of your stake — owning 60% of a $10M company is worth less than owning 20% of a $500M company.
Short for capitalization table. A spreadsheet or document that records who owns what percentage of a company, including founders, investors, employees with equity grants, and any option pools. A clean, well-maintained cap table is essential for fundraising and due diligence.
A financing instrument created by Y Combinator that allows investors to provide capital in exchange for the right to receive equity at a future priced round. SAFEs are simpler and faster to execute than traditional equity rounds, making them popular at the pre-seed stage. They typically include a valuation cap and sometimes a discount.
A short-term debt instrument that converts into equity at a future financing event, typically at a discount to the next round's price. Like SAFEs, convertible notes defer the valuation question, but they carry an interest rate and a maturity date, adding complexity. They are less common at the earliest stages but still used in some life sciences financings.
The gap between academic science and venture-backed company building is real, but it is not as wide as it appears. The skills that make you an exceptional scientist — intellectual rigor, comfort with uncertainty, the ability to design experiments that test hypotheses — are exactly the skills that make great founders. The vocabulary and mechanics of venture capital can be learned. What cannot be taught is the deep scientific insight that comes from years at the bench. That is your advantage. Use it.
Ready to explore what comes after the lab? We're here to help.
Resources for Founders